Shares of Moderna are trading higher Wednesday after Oracle Chairman Larry Ellison discussed the potential of artificial intelligence (AI) to revolutionize healthcare.

Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.

This funding, announced Friday by Moderna, builds on the $176 million it received from HHS last year to support earlier stages of vaccine research.

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of mRNA-based pandemic influenza vaccines, including vaccines for avian flu ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near future ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

Earlier this month, Moderna announced business updates and progress across its pipeline. Moderna says it enters 2025 with a ...

Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.

The funding, which follows the $176 million the government awarded Moderna in June 2024, aims to get mRNA vaccines ready ...

Notable gainers among liquid option names this morning include Moderna (MRNA) $37.05 +2.99, Charles Schwab (SCHW) $81.77 +5.36, Super Micro ...

RNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by the U.S.

The Department of Health and Human Services has granted millions of dollars to Moderna to speed up bird flu vaccine development.